Associations of PRα/LBD and FLT3-ITD mutations and ACAs after relapse On-ATRA or Off-ATRA therapy
| Test parameter . | PRα/LBD mutations . | FLT3-ITD mutations . | ACA . | |||||
|---|---|---|---|---|---|---|---|---|
| Descriptor . | On-ATRA (11 vs 7) . | Off-ATRA (7 vs 16) . | Descriptor . | On-ATRA (6 vs 12) . | Off-ATRA (9 vs 14) . | Descriptor . | Off-ATRA (9 vs 3) . | |
| Presenting WBCs* | Low | ANI | .001 | High | ANI | < .001 | Low | .02 |
| PML-RARα type | — | ANI | ANI | ↑ S-isoform incidence | .05 | .002 | ↑ L-isoform incidence | .05 |
| PRα/LBD+ | — | — | — | Negative association | ANI | .02 | — | ANI |
| FLT3-ITD+ | Negative association | ANI | .02 | — | — | — | Negative association | .005 |
| ACA | — | ANI | ANI | Negative association | ANI | .005 | — | — |
| Test parameter . | PRα/LBD mutations . | FLT3-ITD mutations . | ACA . | |||||
|---|---|---|---|---|---|---|---|---|
| Descriptor . | On-ATRA (11 vs 7) . | Off-ATRA (7 vs 16) . | Descriptor . | On-ATRA (6 vs 12) . | Off-ATRA (9 vs 14) . | Descriptor . | Off-ATRA (9 vs 3) . | |
| Presenting WBCs* | Low | ANI | .001 | High | ANI | < .001 | Low | .02 |
| PML-RARα type | — | ANI | ANI | ↑ S-isoform incidence | .05 | .002 | ↑ L-isoform incidence | .05 |
| PRα/LBD+ | — | — | — | Negative association | ANI | .02 | — | ANI |
| FLT3-ITD+ | Negative association | ANI | .02 | — | — | — | Negative association | .005 |
| ACA | — | ANI | ANI | Negative association | ANI | .005 | — | — |
FLT3-D835 mutations and ACAs after relapse. On-ATRA too few for analysis. Detailed data for all parameters are listed in “Statistical methods” and supplemental Table 10.
— indicates not applicable; and ANI, association not indicated.
WBC high or low P values were calculated from above or below the median WBC (6800/μL).